In breast cancer and gastric cancer, GSDMB is often co-expressed with the HER2/ERBB2 oncogene, and GSDMB overexpression promotes tumor invasion, metastasis, and treatment resistance (Gámez-Chiachio et al., 2022; Hergueta-Redondo et al., 2014; Molina-Crespo et al., 2019; Sarrio et al., 2022). This evidence concerns the gene ERBB2 and breast carcinoma.